Loggia Nicoletta 4

What Happened Nicoletta Loggia, a director of Candel Therapeutics (CADL), was granted a derivative award covering 32,000 shares on June 23, 2026. The Form 4 records the transaction as an award/acquisition (code A) at $0.00 (reported acquisition value $0). This is a time-based equity grant (option/award) as part of director compensation, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-23; Form 4 filed: 2026-06-24 (timely).
• Grant: 32,000 shares (derivative interest) reported at $0.00.
• Shares owned after transaction: not specified in the provided transaction summary.
• Footnote: The option vests on the earlier of (i) June 23, 2027 or (ii) the next Annual Meeting of Stockholders. Vesting stops if the reporting person resigns or ceases to serve as a director unless the Board decides otherwise.
• Transaction code: A = Award/Grant (derivative). No 10b5-1 plan or tax-withholding note indicated.

Context This filing documents a typical director equity grant (time‑based option/award). Because it’s a derivative award that vests over time and no shares were sold or bought on the open market, it should be viewed as routine compensation rather than an immediate market vote by the insider.